Confident Investing Starts With TipRanks Premium

Get 55% Off
TipRanks
Go Ultimate55% OFF

Mabwell (Shanghai) Bioscience Co., Ltd. Class H (2493) Stock Price & Analysis

2493 Stock Chart & Stats

HK$18.49HK$0.26(1.43%)
At close: 4:08 PM GMT+8
HK$18HK$20HK$22HK$243 Aug17 Aug31 Aug14 Sep28 Sep12 Oct26 Oct
Day’s Range
HKD 17.80 - HKD 18.47
52-Week Range
HKD 17.04 - HKD 31.46
Previous Close
HKD 18.60
Volume
N/A
Average Volume (3M)
164.67K
Market Cap
HKD 13.86B
Enterprise Value
HKD 11.43B
Total Cash (Recent Filing)
HKD 2.29B
Total Debt (Recent Filing)
HKD 3.35B
Price to Earnings (P/E)
―
Beta
-0.00
Next Earnings
Apr 07, 2027 (Est.)
EPS Estimate
N/A
Next Dividend Ex-Date
N/A
Dividend Yield
N/A

Bulls Say, Bears Say

Bulls Say

Revenue Growth

Revenue growth of 17.3% indicates improving commercial traction across the company’s biologics business. If sustained, a larger revenue base can support operating leverage, broaden market presence, and provide a stronger foundation for funding continued development and commercialization.

Gross Margin

A gross margin near 74.5% shows that commercial revenue retains substantial value after direct costs. This provides a potentially attractive economic foundation for the business, although the benefit will depend on whether operating expenses can eventually be brought into line with revenue.

Narrowing Losses

The material reduction in losses versus 2023–2024 suggests that financial performance is moving in a better direction, even though the company remains unprofitable. Continued improvement could gradually reduce the funding burden and increase the possibility of reaching sustainable earnings over time.

Bears Say

Deep Operating Losses

Extremely negative EBIT and net margins show that revenue is currently insufficient to cover the company’s operating cost base. Persistent losses weaken internal funding capacity, keep the business dependent on external capital, and make a durable path to profitability a central execution challenge.

Heavy Cash Burn

Large negative operating and free cash flow indicates that the company is not yet funding operations and investment from internally generated cash. Continued cash burn raises ongoing financing requirements and leaves less flexibility to absorb setbacks while the pipeline and commercial business develop.

Elevated Leverage

Debt-to-equity of about 3.84x represents substantial leverage relative to the company’s equity base, despite improvement from the 2025 level. High debt combined with continuing losses can constrain financial flexibility and increase the importance of securing funding while operations remain cash negative.

Mabwell (Shanghai) Bioscience Co., Ltd. Class H News

2493 FAQ

What was Mabwell (Shanghai) Bioscience Co., Ltd. Class H’s price range in the past 12 months?
Mabwell (Shanghai) Bioscience Co., Ltd. Class H lowest stock price was HK$17.04 and its highest was HK$31.46 in the past 12 months.
What is Mabwell (Shanghai) Bioscience Co., Ltd. Class H’s market cap?
Mabwell (Shanghai) Bioscience Co., Ltd. Class H’s market cap is HK$13.86B.
When is Mabwell (Shanghai) Bioscience Co., Ltd. Class H’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were Mabwell (Shanghai) Bioscience Co., Ltd. Class H’s earnings last quarter?
Mabwell (Shanghai) Bioscience Co., Ltd. Class H released its earnings results on Aug 30, 2026. The company reported -HK$0.751 earnings per share for the quarter.
Is Mabwell (Shanghai) Bioscience Co., Ltd. Class H overvalued?
Not enough analysts have published a price target to calculate whether the price is overvalued.
Does Mabwell (Shanghai) Bioscience Co., Ltd. Class H pay dividends?
Mabwell (Shanghai) Bioscience Co., Ltd. Class H does not currently pay dividends.
What is Mabwell (Shanghai) Bioscience Co., Ltd. Class H’s EPS estimate?
Mabwell (Shanghai) Bioscience Co., Ltd. Class H’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Mabwell (Shanghai) Bioscience Co., Ltd. Class H have?
Mabwell (Shanghai) Bioscience Co., Ltd. Class H has 47,130,200 shares outstanding.
What happened to Mabwell (Shanghai) Bioscience Co., Ltd. Class H’s price movement after its last earnings report?
Mabwell (Shanghai) Bioscience Co., Ltd. Class H reported an EPS of -HK$0.751 in its last earnings report. Following the earnings report the stock price went up 0.758%.
Which hedge fund is a major shareholder of Mabwell (Shanghai) Bioscience Co., Ltd. Class H?
Currently, no hedge funds are holding shares in HK:2493
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology